| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
( Department of Pharmacology, Stanford University School of Medicine, Palo Alto, Calif.)
The growth of L-fibroblasts in diffusion chambers implanted intraperitoneally in C3H mice was inhibited by "hyperimmunizing" the host with L-fibroblasts; no significant inhibition was found while reactions analogous to first-set and second-set rejections presumably were occurring in the host outside the diffusion chamber. The serum from "hyperimmunized" C3H mice contained a diffusible (soluble) factor(s) which, when injected into isologous mice, inhibited the growth of L-fibroblasts in diffusion chambers in these animals. These results are consistent with the hypothesis that a circulating growth-inhibitory factor(s), presumably an antibody, may play an important role in the rejection of fibroblast-type cells as well as leukotic-type cells.
* Supported by American Cancer Society Grants T38 and T39 to Dr. Avram Goldstein.
With the Technical Assistance of Ester Bugna
Received 10/ 3/60.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |